Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Nearly five dozen 2019 models meet stricter criteria to qualify for a 2019 TOP SAFETY PICK+ or TOP SAFETY PICK award from the Insurance Institute for Highway Safety. The 30 first-tier “plus” award winners earn the highest rating for passenger-side protection in a small overlap front crash and have good-rated available headlights, while the 27 winners of the second-tier award qualify with an acceptable or higher rating in the newest IIHS crash test and the nighttime headlight evaluation.
All 57 vehicles in this elite group earn good ratings in the Institute’s five other crashworthiness evaluations and have an available automatic emergency braking system that rates advanced or superior for front crash prevention.
IIHS now requires a good rating in the passenger-side small overlap front test to earn a 2019 TOP SAFETY PICK+ versus an acceptable or good rating for the 2018 award. An acceptable or good rating in the passenger-side test is a new criterion to earn a 2019 TOP SAFETY PICK.
This marks the sixth time that IIHS has raised the bar to earn the TOP SAFETY PICK+ award since introducing it in the 2013 model year to recognize vehicles that offer a superior level of safety. The TOP SAFETY PICK accolade launched in the 2006 model year to help consumers identify vehicles with the highest ratings. Over the years, IIHS has added to and strengthened criteria for both awards to encourage manufacturers to speed up safety advances.
Featuring a noted cancer researcher, animal behaviorists and a 14-year-old entrepreneur who developed a new product to ease pets’ separation anxiety, Purina’s second Better With Pets Summit emphasized how technology and scientific advances are leading to a brighter future with our pets. The daylong event, Tuesday, in New York City featured 15 expert presentations on scientific, nutritional and behavioral innovations to help better understand why our lives are better with pets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325551-purina-better-with-pets-summit-2014/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Positive strides have been made since 1995 to advance science literacy in the United States, but teachers and parents agree that more hands-on, experiential learning must be adopted in order to improve science education for future generations, according to the results of the 2015 Bayer Facts of Science Education Survey released today.
For 20 years, Bayer has issued the survey, which assesses science education in the United States and evaluates its development. Although positive strides have been made, survey results emphasize the critical need to improve science education and literacy for future generations. Teachers, for example, universally agree (99 percent) that more hands-on experiential learning in general would benefit student learning.
In response, Bayer is announcing a five-year commitment to provide 1 million hands-on science learning experiences for children by 2020, timed to the 20th anniversary of the Making Science Make Sense® program, Bayer’s company-wide initiative that advances science literacy across the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7452954-bayer-children-science-education/
Swissquote Bank Ltd., Switzerland’s leading online bank, announces the launch of a set of investor tools that help anticipate the impact of the French presidential election on financial markets. A key element is the Social Media Opinion Index, created in cooperation with the Social Media Lab at École polytechnique fédérale de Lausanne (EPFL).
The Index makes use of the latest advances in artificial intelligence to collect and analyze opinions about the candidates in the French election as expressed on social media networks; it allows investors to take the pulse of public online opinion about the candidates, indicating potential outcomes of the elections in real-time.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8083151-french-election-swissquote-epfl-investors/
Leading Mobile Satellite Services (MSS) operator Thuraya Telecommunications today made further advances in satellite phone capability with the launch of the world’s first dual mode, dual SIM phone.
The Thuraya XT-PRO DUAL bridges the gap between satellite and terrestrial communications, allowing users to move seamlessly in and out of terrestrial coverage to enjoy connectivity in any location. With a dedicated SIM slot for satellite communications and a second one for GSM communications, Thuraya’s latest groundbreaking handset transforms usability and choice. Users can opt for a Thuraya SIM card and their GSM card, or select any combination of SIM cards that meets their requirements.
Versatility has been taken to unprecedented levels, too. The new handset’s ‘Always On’ capability lets users alternate between calls effortlessly, ensuring they are always reachable on both the satellite and the terrestrial networks. Callers can be contacted on their GSM number even while on an active satellite call – and vice versa.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7976651-thuraya-xt-pro-launch-dual-mode-sim-phone/
Hutchinson Plumbing Heating Cooling is South Jersey’s largest heating, ventilation and air conditioning company. For generations they have had the opportunity to provide the community, both residential and commercial with services, repairs and replacements whenever there was an issue. Over the years as a family owned business, Hutchinson continues to stay up to date on all the latest advances, laws and regulations so property owners are receiving the highest quality of services and equipment. http://www.hutchbiz.com/
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials.
One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances.
Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LLS is committed to funding and recognizing female scientists, physicians, social workers and nurses, and encouraging young women to participate in STEM (science, technology, engineering and math) education and pursue careers in the sciences.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128552-lls-women-in-science/
REMBRANDT®, the original teeth whitening brand, advances the at-home whitening category with the launch of a new 1 Week Whitening Kit and 3 Day Whitening Boost Kit that provide visibly whiter smiles from the comfort of home in half the time of traditional 14-day kits.
Perfect for whitening with short notice before a big event or special occasion, the kits arrive online at Rembrandt.com this month at a suggested retail price of $24.99 and $6.99 each, respectively. The 1 Week Whitening Kit is available in-store exclusively at Walmart today and will arrive in Harmon Face Values and select Bed Bath & Beyond stores in late October.
To view the multimedia release go to:
https://www.multivu.com/players/English/8165651-rembrandt-stayput-custom-fit-whitening-strips/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
